Johnson & Johnson proposes $6.5bn settlement of talc cancer lawsuits

Johnson & Johnson is moving forward with a $6.475bn proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer.

The deal would allow it to resolve the lawsuits through a third bankruptcy filing of a subsidiary company. It will begin a three-month voting period in hopes of reaching consensus on a settlement of all current and future ovarian cancer claims.

Ovarian cancer claims account for 99% of the talc-related lawsuits filed against J&J, including about 54,000 lawsuits that are centralized in a New Jersey federal court proceeding.

Courts have rebuffed J&J’s two previous efforts to resolve the lawsuits through the bankruptcy of the subsidiary created to absorb J&J’s talc liability, LTL Management.

J&J, which says that its products do not contain asbestos and do not cause cancer, said that its settlement has the support of a majority of attorneys representing plaintiffs who have filed cancer lawsuits against the company.

J&J said it was confident that the deal would reach a 75% support threshold needed for a bankruptcy settlement that would end the litigation entirely, shutting off future lawsuits and preventing people from opting out of the deal to pursue their separate lawsuits.

The proposed deal would build on J&J’s settlements with about 95% of people who have sued the company after developing mesothelioma, a rare form of cancer linked to asbestos exposure, as well as its settlements with US states, which have alleged that the company failed to warn consumers about the dangers of its talc products.

J&J did not disclose the value of the mesothelioma settlements, but it said that it recorded an incremental charge of $2.7bn in the first quarter of 2024, to account for recent talc-related settlements.

J&J said it would continue to defend itself against the lawsuits while trying to gather votes on the settlement. The company said it had prevailed in 95% of ovarian cases tried to date, including every ovarian case tried over the last six years.

skip past newsletter promotion

But, the litigation has resulted in some large verdicts for plaintiffs, including a $2.12bn award in favor of 22 women who blamed their ovarian cancer on asbestos in J&J talc. In the past month, J&J was recently ordered to pay $45m in a mesothelioma case while winning an ovarian cancer case.